Company Overview - Channel Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain [3] - The company's initial clinical focus is on selectively targeting the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks [3] Financial Disclosure - The company disclosed in its Annual Report on Form 10-K for the year ended December 31, 2024, that the audited financial statements included an audit opinion from its independent registered public accounting firm that contained a going concern emphasis of matter paragraph [1] - This announcement does not represent any change or amendment to the company's consolidated financial statements or to its Annual Report on Form 10-K for the year ended December 31, 2024 [2] Regulatory Compliance - The release of this information is required by Sections 410(h) and 610(b) of the NYSE American LLC Company Guide [2]
Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules